The latest price and price reduction policy of fenelidone in 2025

Finerenone is an innovative drug developed by the German company Bayer. It is currently on the market in mainland China and has been included in the Class B management of the National Reimbursement Directory. This means that patients can enjoy partial reimbursement when used within the scope of medical insurance, which greatly reduces the financial burden. The most common specifications in the domestic market include 10mg*14 tablets and 20mg*7 tablets. The actual price paid after medical insurance is about 300 yuan to 500 yuan per box, which fluctuates due to slight differences in regional medical insurance policies. This price has obvious advantages compared with overseas markets and reflects the effectiveness of the medical insurance negotiation mechanism.

Overseas, such as the American version, European version or Japanese versionThe price of Finerenone is generally high. For example, the price of a 100-piece package in the Japanese market is about RMB 2,000, while the US version is even higher. These prices are greatly affected by the original manufacturer's pricing policy, medical system structure and exchange rate fluctuations, and are usually obtained through self-pay channels. It should be noted that although the overseas version has various dosage specifications, it is not included in local medical insurance, resulting in a generally heavy burden on patients.

In addition to the original drug, several pharmaceutical manufacturers in Laos and other countries have launched generic versions of Finerenone. For example, the price of 30-piece packaged generic drugs produced by Lucius and Daxiong Pharmaceutical in Laos is about 200 yuan, which is highly cost-effective. These generic drugs are usually basically the same in ingredients as the original drugs, but have not yet been formally approved in China. Therefore, they are mainly obtained through cross-border drug purchase, overseas medical treatment or third-party pharmaceutical service platforms. When choosing such drugs, patients should carefully screen the sources and ensure that the drug purchase channels are legal and compliant to ensure drug quality and therapeutic effects.

To sum up, fenelidone currently has a price advantage in the Chinese market, and medical insurance coverage and market competition will continue to optimize drug accessibility. When purchasing drugs, patients should mainly use hospital and pharmacy channels to ensure drug safety, and at the same time, adjust treatment plans according to disease progression under the guidance of a doctor.

Reference materials:https://www.kerendia.com/